Company profile for ADvantage Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). We are currently preparing for clinical trials in Europe and in the US. Furthermore, ADvantage is developing potentially paradigm-changing therapies to treat AD in its labs at the Vienna BioCenter.Our work suggests that our lead therapeutic (AD04™) regulates the immune system to provide patie...
ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). We are currently preparing for clinical trials in Europe and in the US. Furthermore, ADvantage is developing potentially paradigm-changing therapies to treat AD in its labs at the Vienna BioCenter.Our work suggests that our lead therapeutic (AD04™) regulates the immune system to provide patients with a unique positive effect on the course of Alzheimer’s Disease pathology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/09/3163980/0/en/Dr-Mark-Hyman-joins-ADvantage-Therapeutics-Advisory-Board-to-further-advance-Klotho-Based-Longevity-Programs-at-Klothea-Bio.html

GLOBENEWSWIRE
09 Oct 2025

https://www.globenewswire.com/news-release/2025/09/26/3157020/0/en/UPDATE-ADvantage-Therapeutics-Awarded-2-5-Million-NIH-SBIR-Grant-to-Advance-Alzheimer-s-Drug-Candidate-AD04-Toward-the-Clinic.html

GLOBENEWSWIRE
26 Sep 2025

https://www.globenewswire.com/news-release/2024/11/25/2986807/0/en/Advantage-Therapeutics-Inc-Announces-Formation-of-Klothea-Bio-Inc-to-Advance-Research-and-Development-of-Klotho-Protein-for-Age-Related-Therapeutics.html

GLOBENEWSWIRE
25 Nov 2024

https://www.globenewswire.com/news-release/2024/09/09/2942957/0/en/ADvantage-Therapeutics-Inc-Welcomes-Dr-William-A-Haseltine-as-Strategic-Advisor-to-Drive-Innovation-in-Alzheimer-s-Disease-Research-and-Anti-aging-Therapies-such-as-Klotho-Protein-.html

GLOBENEWSWIRE
09 Sep 2024

https://www.globenewswire.com/news-release/2024/07/30/2921254/0/en/ADvantage-Therapeutics-Announces-Breakthrough-Findings-in-Alzheimer-s-Disease-Treatment-AD04TM-shows-immediate-symptomatic-and-disease-modifying-properties.html

GLOBENEWSWIRE
30 Jul 2024

https://www.globenewswire.com//news-release/2024/02/05/2823613/0/en/Discoverer-of-the-Klotho-Gene-and-Pioneer-in-Longevity-and-Disease-Prevention-Dr-Makoto-Kuro-o-Joins-Scientific-Advisory-Board-of-ADvantage-Therapeutics.html

GLOBENEWSWIRE
05 Feb 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty